Lenabasum

Lenabasum is a synthetic, orally available, selective cannabinoid receptor type 2 (CB2) agonist. It is being developed as a treatment for various fibrotic and autoimmune diseases.

Lenabasum works by binding to and activating the CB2 receptor, which is primarily expressed on immune cells and fibroblasts. Activation of the CB2 receptor by lenabasum is thought to reduce inflammation, inhibit fibrosis (scarring), and modulate immune responses. Unlike agonists of the CB1 receptor (the primary cannabinoid receptor in the brain), lenabasum does not produce psychoactive effects.

Lenabasum has been studied in clinical trials for the treatment of systemic sclerosis, diffuse cutaneous systemic sclerosis (dcSSc), dermatomyositis, cystic fibrosis, and other conditions. While some trials have shown promising results in specific patient populations or endpoints, others have not met their primary endpoints. The development of lenabasum has involved multiple pharmaceutical companies.